Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1

Zhang, Yue; Li, Jiang; Huang, Yixian; Chen, Yuang; Luo, Zhangyi; Huang, Haozhe; West, Raymond E.; Nolin, Thomas D.; Wang, Zhou; Li, Song

doi:10.7150/thno.76614



Nanotheranostics 2024; 8(3): 380-400. [Abstract] [Full text] [PDF]

Nanotheranostics 2024; 8(3): 344-379. [Abstract] [Full text] [PDF] [PubMed] [PMC]

Nanotheranostics

International Journal of Biological Sciences

International Journal of Medical Sciences

Journal of Cancer

Global reach, higher impact

Full Text | PDF

Theranostics 2023; 13(2):578-595. doi:10.7150/thno.76614 This issue Cite

Research Paper

Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1

Yue Zhang^1#, Jiang Li^1#, Yixian Huang¹, Yuang Chen¹, Zhangyi Luo¹, Haozhe Huang¹, Raymond E. West III², Thomas D. Nolin², Zhou Wang³, Song Li^1✉

1. Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15261.
2. Small Molecule Biomarker Core (SMBC), Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15261.
3. Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261.
#Authors contributed equally to the work.

Citation:

Zhang Y, Li J, Huang Y, Chen Y, Luo Z, Huang H, West RE III, Nolin TD, Wang Z, Li S. Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1. Theranostics 2023; 13(2):578-595. doi:10.7150/thno.76614. https://www.thno.org/v13p0578.htm

Other styles

Abstract

Inhibition of Myc promotes the regression of many types of tumors, including prostate cancer. However, the success of anti-Myc therapy is hampered by the lack of a strategy to effectively deliver the inhibitors to the tumor site and by the feedback mechanisms that cancer cells use to adapt to metabolic reprogramming.

Methods: The effects of Myc inhibitors (10074-G5 or 10058-F4), alone or in combination with 6-diazo-5-oxo-L-norleucine (DON), were evaluated in cultured human or murine prostate cancer cells by cell viability assay, qRT-PCR and Western blot. To facilitate the in vivo therapeutic evaluation, a prodrug conjugate of 10074-G4 and DON (10074-DON) was developed, which could be effectively loaded into a polysaccharide-based nanocarrier (PS).

Results: The treatment with Myc inhibitors led to significant induction of glutamine: fructose-6-phosphate amidotransferase-1 (GFAT1) and enhanced protein glycosylation. Mechanistically, Myc inhibition triggered GFAT1 induction through the IREα-Xbp1s pathway. The combination use of Myc inhibitors and GFAT1 inhibitor DON led to a synergistic effect in inhibiting the proliferation and migration of prostate cancer cells. Enhanced in vivo delivery of 10074-DON via the PS nanocarrier led to a significant inhibition of tumor growth along with an improvement in tumor immune microenvironment in several PCa animal models.

Conclusion: Simultaneous targeting of Myc and GFAT-1 may represent a novel strategy for the treatment of prostate cancer.

Keywords: Myc, glutamine: fructose-6-phosphate amidotransferase-1, protein glycosylation, prostate cancer, therapy

Citation styles

APA

Zhang, Y., Li, J., Huang, Y., Chen, Y., Luo, Z., Huang, H., West, R.E. III, Nolin, T.D., Wang, Z., Li, S. (2023). Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1. Theranostics, 13(2), 578-595. https://doi.org/10.7150/thno.76614.

ACS

Zhang, Y.; Li, J.; Huang, Y.; Chen, Y.; Luo, Z.; Huang, H.; West, R.E. III; Nolin, T.D.; Wang, Z.; Li, S. Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1. Theranostics 2023, 13 (2), 578-595. DOI: 10.7150/thno.76614.

NLM

CSE

Zhang Y, Li J, Huang Y, Chen Y, Luo Z, Huang H, West RE III, Nolin TD, Wang Z, Li S. 2023. Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1. Theranostics. 13(2):578-595.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.